GREENWICH LIFESCIENCES, INC. Operating Cash Flow
GREENWICH LIFESCIENCES, INC. (GLSI) reported Operating Cash Flow of -$6.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.94M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.70M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.17M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.67M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$9.91M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$7.27M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$6.48M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$6.20M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$6.64M 10-Q · filed 2026-08-11 | -$9.82M derived: sum of 3 quarters · filed 2026-08-11 | -$12.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$4.70M 10-Q · filed 2026-06-04 | -$7.88M derived: sum of 2 quarters · filed 2026-06-04 | -$10.55M derived: sum of 3 quarters · filed 2026-06-04 | -$12.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$3.17M derived: 10-K 12 month − 10-K 9 month · filed 2026-06-01 | -$5.85M derived: sum of 2 quarters · filed 2026-06-01 | -$8.08M derived: sum of 3 quarters · filed 2026-08-11 | -$9.91M 10-K · filed 2026-06-01 |
| 2025-09-30 | -$2.67M derived: 10-K 9 month − 10-Q 6 month · filed 2026-06-01 | -$4.90M derived: sum of 2 quarters · filed 2026-08-11 | -$6.74M 10-K · filed 2026-06-01 | -$8.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.07M 10-Q · filed 2026-08-11 | -$5.92M derived: sum of 3 quarters · filed 2026-08-11 | -$8.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.83M 10-Q · filed 2026-06-04 | -$3.69M derived: sum of 2 quarters · filed 2026-06-04 | -$6.27M derived: sum of 3 quarters · filed 2026-06-04 | -$7.32M derived: sum of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$4.44M derived: sum of 2 quarters · filed 2026-06-01 | -$5.48M derived: sum of 3 quarters · filed 2026-06-01 | -$7.27M 10-K · filed 2026-06-01 |
| 2024-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$3.63M derived: sum of 2 quarters · filed 2025-11-14 | -$5.41M 10-Q · filed 2025-11-14 | -$7.57M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.83M 10-Q · filed 2025-08-14 | -$4.98M derived: sum of 3 quarters · filed 2025-08-14 | -$6.79M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.78M 10-Q · filed 2025-05-20 | -$3.94M derived: sum of 2 quarters · filed 2025-05-20 | -$5.74M derived: sum of 3 quarters · filed 2025-05-20 | -$6.70M derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$3.95M derived: sum of 2 quarters · filed 2025-04-15 | -$4.92M derived: sum of 3 quarters · filed 2025-04-15 | -$6.48M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.77M derived: sum of 2 quarters · filed 2024-11-14 | -$4.32M 10-Q · filed 2024-11-14 | -$6.49M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$966.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.52M 10-Q · filed 2024-08-14 | -$4.69M derived: sum of 3 quarters · filed 2024-08-14 | -$6.24M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$1.56M 10-Q · filed 2024-05-20 | -$3.73M derived: sum of 2 quarters · filed 2024-05-20 | -$5.28M derived: sum of 3 quarters · filed 2024-05-20 | -$5.81M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | -$3.72M derived: sum of 2 quarters · filed 2024-04-15 | -$4.25M derived: sum of 3 quarters · filed 2024-04-15 | -$6.20M 10-K · filed 2024-04-15 |
| 2022-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | -$2.08M derived: sum of 2 quarters · filed 2023-10-19 | -$4.03M 10-Q · filed 2023-10-19 | -$6.29M derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | -$532.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$2.48M 10-Q · filed 2023-08-21 | -$4.74M derived: sum of 3 quarters · filed 2023-08-21 | -$5.64M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$1.95M 10-Q · filed 2023-05-22 | -$4.21M derived: sum of 2 quarters · filed 2023-05-22 | -$5.11M derived: sum of 3 quarters · filed 2023-05-22 | -$5.71M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.16M derived: sum of 2 quarters · filed 2023-03-31 | -$3.76M derived: sum of 3 quarters · filed 2023-03-31 | -$4.29M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$894.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.50M derived: sum of 2 quarters · filed 2022-11-14 | -$2.03M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$604.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.13M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$528.27K 10-Q · filed 2022-05-20 | |||
| 2020-12-31 | -$1.15M 10-K · filed 2022-03-21 | |||
| 2019-12-31 | -$214.17K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$293.27K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | -$79.10K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |